Minoxidil : interactions médicamenteuses

Minoxidil (Loniten, Rogaine), vasodilatateur, présente 192 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 96 de niveau majeur, 73 de niveau modéré, 23 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (96)

  • AcébutololbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Acétazolamideinhibiteur de l'anhydrase carboniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Acide étacryniquediurétique de l'anseMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • AliskirèneantihypertenseurMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Amiloridediurétique épargneur de potassiumMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Amlodipineinhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Amlodipine et atorvastatineinhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Amlodipine et bénazéprilinhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Amlodipine et olmésartaninhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Amlodipine et valsartaninhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • AténololbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Aténolol et chlortalidonebêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Azilsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Bénazéprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • BétaxololbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • BisoprololbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Brimonidine et timololagoniste alpha-adrénergiqueMajeure

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (notice Minoxidil, Mise en garde encadrée)

  • Bumétanidediurétique de l'anseMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Candésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Captoprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • CarvédilolbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Chlorothiazidediurétique thiazidiqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Chlortalidonediurétique thiazidiqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Clonidineagoniste alpha-adrénergiqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • ClozapineantipsychotiqueMajeure

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (notice Clozapine, Mise en garde encadrée)

  • Diltiazeminhibiteur calciqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Dorzolamide et timololinhibiteur de l'anhydrase carboniqueMajeure

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (notice Minoxidil, Mise en garde encadrée)

  • DoxazosinealphabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Énalaprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Énalaprilateinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Éplérénoneantagoniste de l'aldostéroneMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Eptifibatideantiagrégant plaquettaireMajeure

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (notice Eptifibatide, Contre-indications)

  • EsmololbêtabloquantMajeure

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (notice Minoxidil, Mise en garde encadrée)

  • Félodipineinhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Fosinoprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Furosémidediurétique de l'anseMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Guanfacineagoniste alpha-adrénergiqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • HydralazinevasodilatateurMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Hydrochlorothiazidediurétique thiazidiqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Indapamidediurétique thiazidiqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Irbésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Isradipineinhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • LabétalolbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Lisinoprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Lofexidineagoniste alpha-adrénergiqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Losartanantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • MécamylamineantihypertenseurMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • MéthyldopaantihypertenseurMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Métolazonediurétique thiazidiqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • MétoprololbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Moexiprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • NadololbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • NébivololbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Nicardipineinhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Nifédipineinhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Nisoldipineinhibiteur calcique dihydropyridiniqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Nitroprussiate de sodiumvasodilatateurMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Olmésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Périndoprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • PhénoxybenzaminealphabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • PindololbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • PrazosinealphabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • PropranololbêtabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Quinaprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Ramiprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Sacubitril et valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • SotalolbêtabloquantMajeure

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (notice Minoxidil, Mise en garde encadrée)

  • Spironolactoneantagoniste de l'aldostéroneMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Tadalafilinhibiteur de la PDE5Majeure

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (notice Tadalafil, Mises en garde et précautions)

  • Telmisartanantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Telmisartan et amlodipineantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • TérazosinealphabloquantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • TimololbêtabloquantMajeure

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (notice Minoxidil, Mise en garde encadrée)

  • TizanidinemyorelaxantMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Torasémidediurétique de l'anseMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Trandolaprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Triamtérènediurétique épargneur de potassiumMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • Vérapamilinhibiteur calciqueMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

Interactions modérées (73)

  • Acide méfénamiqueAINSModérée

    Intervention: During concomitant use of mefenamic acid with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.6 )] . (notice Acide méfénamique, Interactions médicamenteuses)

  • AdénosineantiarythmiqueModérée

    Hypotension Adenosine injection is a potent peripheral vasodilator and can induce significant hypotension. (notice Adénosine, Mises en garde et précautions)

  • AdrénalinesympathomimétiqueModérée

    Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (notice Adrénaline, Interactions médicamenteuses)

  • AlfuzosinealphabloquantModérée

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (notice Alfuzosine, Mises en garde et précautions)

  • Amfépramonestimulant du SNCModérée

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (notice Amfépramone, Interactions médicamenteuses)

  • AripiprazoleantipsychotiqueModérée

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (notice Aripiprazole, Interactions médicamenteuses)

  • Armodafinilstimulant du SNCModérée

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (notice Armodafinil, Mises en garde et précautions)

  • AsénapineantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (notice Asénapine, Mises en garde et précautions)

  • Atomoxétineinhibiteur de la recapture de la noradrénalineModérée

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (notice Atomoxétine, Interactions médicamenteuses)

  • Avanafilinhibiteur de la PDE5Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Benzfétaminestimulant du SNCModérée

    Amphetamines may decrease the hypotensive effect of antihypertensives. (notice Benzfétamine, Interactions médicamenteuses)

  • BortézomibModérée

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (notice Bortézomib, Mises en garde et précautions)

  • BrexpiprazoleantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (notice Brexpiprazole, Mises en garde et précautions)

  • Brimonidineagoniste alpha-adrénergiqueModérée

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (notice Brimonidine, Interactions médicamenteuses)

  • Bromocriptineagoniste de la dopamineModérée

    Use caution in patients taking antihypertensive medications. (notice Bromocriptine, Mises en garde et précautions)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (notice Bromphéniramine, pseudoéphédrine et dextrométhorphane, Interactions médicamenteuses)

  • CarbidopaModérée

    Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (notice Carbidopa, Interactions médicamenteuses)

  • Carbidopa et lévodopamédicament dopaminergiqueModérée

    Antihypertensive drugs: May cause symptomatic postural hypotension. (notice Carbidopa et lévodopa, Interactions médicamenteuses)

  • Carbidopa, lévodopa et entacaponemédicament dopaminergiqueModérée

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (notice Carbidopa, lévodopa et entacapone, Interactions médicamenteuses)

  • CariprazineantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (notice Cariprazine, Mises en garde et précautions)

  • CélécoxibAINSModérée

    Intervention: During concomitant use of VYSCOXA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]. (notice Célécoxib, Interactions médicamenteuses)

  • CiclosporineimmunosuppresseurModérée

    If hypertension persists, the dose of Neoral should be further reduced or blood pressure should be controlled with antihypertensive agents. (notice Ciclosporine, Précautions)

  • CyclobenzaprinemyorelaxantModérée

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (notice Cyclobenzaprine, Interactions médicamenteuses)

  • Dexmédétomidineagoniste alpha-adrénergiqueModérée

    • Co-administration with Other Vasodilators or Negative Chronotropic Agents : Use with caution due to additive pharmacodynamic effects. (notice Dexmédétomidine, Mises en garde et précautions)

  • Dexméthylphénidatestimulant du SNCModérée

    • Antihypertensive Drugs: Monitor blood pressure. (notice Dexméthylphénidate, Interactions médicamenteuses)

  • DiclofénacAINSModérée

    Intervention: During concomitant use of ZIPSOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (notice Diclofénac, Interactions médicamenteuses)

  • Intervention: During concomitant use of diclofenac sodium/misoprostol with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.7) ] . (notice Diclofénac et misoprostol, Interactions médicamenteuses)

  • Dinitrate d'isosorbidedérivé nitréModérée

    Drug Interactions The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators. (notice Dinitrate d'isosorbide, Interactions médicamenteuses)

  • DuloxétineIRSNaModérée

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (notice Duloxétine, Mises en garde et précautions)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Époprosténolanalogue de prostaglandineModérée

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (notice Époprosténol, Interactions médicamenteuses)

  • FénoprofèneAINSModérée

    Intervention: During concomitant use of FENOPROFEN CALCIUM with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (notice Fénoprofène, Interactions médicamenteuses)

  • FlurbiprofèneAINSModérée

    Intervention: During concomitant use of flurbiprofen with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5) ]. (notice Flurbiprofène, Interactions médicamenteuses)

  • During concomitant use of hydrocodone bitartrate and ibuprofen tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS: Renal Toxicity and Hyperkalemia ). (notice Hydrocodone et ibuprofène, Interactions médicamenteuses)

  • IbuprofèneAINSModérée

    Intervention: During concomitant use of CALDOLOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (notice Ibuprofène, Interactions médicamenteuses)

  • Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (notice Ibuprofène et famotidine, Interactions médicamenteuses)

  • IlopéridoneantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (notice Ilopéridone, Mises en garde et précautions)

  • IndométacineAINSModérée

    Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 ) (notice Indométacine, Interactions médicamenteuses)

  • LumatépéroneantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (notice Lumatépérone, Mises en garde et précautions)

  • LurasidoneantipsychotiqueModérée

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (notice Lurasidone, Mises en garde et précautions)

  • MéloxicamAINSModérée

    Intervention: During concomitant use of QAMZOVA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (notice Méloxicam, Interactions médicamenteuses)

  • Méthylphénidatestimulant du SNCModérée

    Antihypertensive Drugs: Monitor blood pressure. (notice Méthylphénidate, Interactions médicamenteuses)

  • MirtazapineantidépresseurModérée

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (notice Mirtazapine, Mises en garde et précautions)

  • Modafinilstimulant du SNCModérée

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (notice Modafinil, Mises en garde et précautions)

  • Mononitrate d'isosorbidedérivé nitréModérée

    The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators. (notice Mononitrate d'isosorbide, Interactions médicamenteuses)

  • NaproxèneAINSModérée

    ( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (notice Naproxène, Mises en garde et précautions)

  • Intervention : During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6) ]. (notice Naproxène et ésoméprazole, Interactions médicamenteuses)

  • NiacineModérée

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (notice Niacine, Interactions médicamenteuses)

  • Nimodipineinhibiteur calcique dihydropyridiniqueModérée

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (notice Nimodipine, Interactions médicamenteuses)

  • OlanzapineantipsychotiqueModérée

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (notice Olanzapine, Mises en garde et précautions)

  • Olanzapine et fluoxétineantipsychotiqueModérée

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (notice Olanzapine et fluoxétine, Mises en garde et précautions)

  • OxaprozineAINSModérée

    Intervention: During concomitant use of OXAPROZIN CAPSULES with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]. (notice Oxaprozine, Interactions médicamenteuses)

  • PalipéridoneantipsychotiqueModérée

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (notice Palipéridone, Mises en garde et précautions)

  • • Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (notice Paracétamol et ibuprofène, Mises en garde et précautions)

  • PazopanibModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • PentoxifyllineméthylxanthineModérée

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (notice Pentoxifylline, Interactions médicamenteuses)

  • PhénelzineIMAOModérée

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (notice Phénelzine, Mises en garde)

  • PiroxicamAINSModérée

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (notice Piroxicam, Interactions médicamenteuses)

  • QuétiapineantipsychotiqueModérée

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (notice Quétiapine, Mises en garde et précautions)

  • RiociguatvasodilatateurModérée

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (notice Riociguat, Mises en garde et précautions)

  • RispéridoneantipsychotiqueModérée

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (notice Rispéridone, Mises en garde et précautions)

  • Sildénafilinhibiteur de la PDE5Modérée

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

  • SilodosinealphabloquantModérée

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (notice Silodosine, Mises en garde et précautions)

  • SorafénibModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Monitor patients to assure diuretic efficacy including antihypertensive effects. (notice Sumatriptan et naproxène, Interactions médicamenteuses)

  • SunitinibModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • TacrolimusimmunosuppresseurModérée

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (notice Tacrolimus, Mises en garde et précautions)

  • TestostéroneandrogèneModérée

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (notice Testostérone, Mises en garde et précautions)

  • TrazodoneantidépresseurModérée

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (notice Trazodone, Mises en garde et précautions)

  • Trinitrinedérivé nitréModérée

    Antihypertensives: Possible additive hypotensive effects. (notice Trinitrine, Interactions médicamenteuses)

  • Vardénafilinhibiteur de la PDE5Modérée

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (notice Vardénafil, Mises en garde et précautions)

  • VenlafaxineIRSNaModérée

    Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (notice Venlafaxine, Interactions médicamenteuses)

  • ZiprasidoneantipsychotiqueModérée

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (notice Ziprasidone, Mises en garde et précautions)

Mentions mineures (23)

  • ButorphanolopioïdeMineure

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (notice Butorphanol, Mises en garde)

  • ChlorpromazineantipsychotiqueMineure

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (notice Chlorpromazine, Mises en garde)

  • Désipramineantidépresseur tricycliqueMineure

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (notice Désipramine, Mises en garde)

  • Désogestrel et éthinylestradiolcontraceptif oralMineure

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (notice Désogestrel et éthinylestradiol, Mises en garde)

  • Dexamfétaminestimulant du SNCMineure

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (notice Dexamfétamine, Interactions médicamenteuses)

  • DiflunisalAINSMineure

    Drug Interactions ACE-inhibitors and Angiotensin II Anagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (notice Diflunisal, Interactions médicamenteuses)

  • Dutastéride et tamsulosineinhibiteur de la 5-alpha-réductaseMineure

    Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure. (notice Dutastéride et tamsulosine, Mises en garde et précautions)

  • ÉphédrinesympathomimétiqueMineure

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (notice Éphédrine, Interactions médicamenteuses)

  • ÉtodolacAINSMineure

    Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (notice Étodolac, Interactions médicamenteuses)

  • IcatibantMineure

    ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (notice Icatibant, Interactions médicamenteuses)

  • KétoprofèneAINSMineure

    ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (notice Kétoprofène, Mises en garde et précautions)

  • KétorolacAINSMineure

    Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. (notice Kétorolac, Interactions médicamenteuses)

  • MéthohexitalbarbituriqueMineure

    Post injury arterial injection of vasodilators and/or arterial infusion of parenteral fluids are generally regarded to be of no value in altering outcome. (notice Méthohexital, Mises en garde)

  • MexilétineantiarythmiqueMineure

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (notice Mexilétine, Interactions médicamenteuses)

  • NabumétoneAINSMineure

    Drug Interactions: ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (notice Nabumétone, Interactions médicamenteuses)

  • Nortriptylineantidépresseur tricycliqueMineure

    The antihypertensive action of guanethidine and similar agents may be blocked. (notice Nortriptyline, Mises en garde)

  • ProchlorpérazineantipsychotiqueMineure

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (notice Prochlorpérazine, Précautions)

  • Protriptylineantidépresseur tricycliqueMineure

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (notice Protriptyline, Mises en garde)

  • SalsalateAINSMineure

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (notice Salsalate, Interactions médicamenteuses)

  • SulindacAINSMineure

    Drug Interactions ACE-Inhibitors and Angiotensin II Antagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (notice Sulindac, Interactions médicamenteuses)

  • TamsulosinealphabloquantMineure

    Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (notice Tamsulosine, Mises en garde et précautions)

  • TolmétineAINSMineure

    DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. (notice Tolmétine, Interactions médicamenteuses)

  • TrifluopérazineantipsychotiqueMineure

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (notice Trifluopérazine, Précautions)

Vérifiez Minoxidil avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.